Previous Article | Next Article 
Journal of Virology, September 1998, p. 7688-7691, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Preactivation of B Lymphocytes Does Not Enhance
Mouse Mammary Tumor Virus Infection
Daniela
Finke,1
Laure
Mortezavi,1 and
Hans
Acha-Orbea1,2,*
Ludwig Institute for Cancer Research,
Lausanne Branch,1 and
Institute for
Biochemistry,2 University of Lausanne, 1066 Epalinges, Switzerland
Received 20 November 1997/Accepted 10 June 1998
 |
ABSTRACT |
We investigated whether mouse mammary tumor virus (MMTV) favors
preactivated or naive B cells as targets for efficient infection. We
have demonstrated previously that MMTV activates B cells upon infection. Here, we show that polyclonal activation of B cells leads
instead to lower infection levels and attenuated superantigen-specific T-cell responses in vivo. This indicates that naive small resting B
cells are the major targets of MMTV infection and that the activation induced by MMTV is sufficient to allow efficient infection.
 |
TEXT |
Mouse mammary tumor virus (MMTV) is
an oncogenic type B retrovirus which infects mainly B lymphocytes
(4, 21). In the first hours after encounter with MMTV, a
polyclonal T-cell-independent B-cell activation is observed
(2). As much as 80% of B cells are activated by MMTV, but
only a few of them become infected. The few infected B lymphocytes
present a viral superantigen (Sag) bound to major histocompatibility
complex (MHC) class II molecules to T cells expressing a specific
T-cell receptor V
element. Subsequent Sag-specific T-helper-cell
responses result in a strong preferential amplification and
differentiation of infected B cells (for a review, see reference
21).
In all known retroviral infections, activated or cycling lymphocytes
are required for infection to occur. For murine leukemia virus, Rous
sarcoma virus, and spleen necrosis virus, the cell cycle of the target
cells has been found to be necessary for viral integration and
productive infection (3, 12, 14, 26). In addition,
retroviral transcription requires an integrated proviral template
(8). While nuclear breakdown during mitosis was shown to
contribute to the integration of retroviral DNA into the nucleus, human
immunodeficiency virus (HIV) has been shown to be independent of
mitosis due to its karyophilic core protein (7). However, HIV requires T-lymphocyte activation for infection. In HIV infection, the inefficient reverse transcription in quiescent peripheral blood
lymphocytes is caused by low levels of deoxynucleotides and contributes
to a cytoplasmatic pool of mostly incomplete viral DNA which can be
rescued after mitogenic stimulation (13).
For MMTV infection, there are two main interpretations for the early
infection events. Either MMTV-induced activation facilitates infection
of naive small resting B cells, or, alternatively, MMTV preferentially
infects preactivated B cells. To address this question, we analyzed the
effect of polyclonal B-cell stimulation on MMTV infection in mice.
To activate B lymphocytes, 7- to 8-week-old BALB/c mice were injected
subcutaneously (s.c.) into the hind footpad with a single dose of
either lipopolysaccharide (LPS) from Escherichia coli (Sigma, San Diego, Calif.) or monoclonal antibodies (MAbs) that induce
a polyclonal B-cell stimulation via cross-linking of surface immunoglobulin (sIg) or CD40.
The following mitogenic MAbs were used in this study: b-7-6 (rat
anti-mouse µ IgG1) (18), 1.19 (rat anti-mouse
IgG2a) (5), or FGK 45 (anti-mouse CD40) (27). 2.4G2, a
rat IgG2b that binds to mouse Fc
RII, was injected s.c. prior to
injection of the other MAbs in order to avoid binding of IgG to
Fc
RII (29). Blocking of Fc
RII binding prevents
induction of B-cell unresponsiveness (25) and by itself has
no influence on MMTV infection and B-cell activation (Fig.
1 and data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
Mitogen-induced B-cell activation and proliferation. A
single dose of 2.4G2 (28 µg) or LPS (10 µg) was injected s.c. into
the hind footpads of BALB/c mice, or mice were left untreated (c').
Anti-IgD MAb (50 µg), anti-CD40 (50 µg), anti-IgD plus anti-CD40
(50 µg each), or anti-IgM (10 µg) was injected s.c. into the hind
footpad 30 min after injection of 2.4G2 (28 µg). The percentages of
CD69+ B cells (A) and BrdU+ B cells (B) among
B220+ B cells in the draining PO-LN were analyzed
24 ( ) and 48 ( ) h later. Each column represents the mean
percentage ± standard deviation of B cells from four mice.
|
|
Induction of B-cell proliferation and differentiation by either LPS or
cross-linking of sIg have been described previously (1, 6, 11, 24,
28). While the earliest biochemical events that parallel B-cell
activation occur within seconds, events that reflect entry into the
G1 phase of the cell cycle occur within a few hours
(9). Accordingly, we analyzed the percentage of B cells
expressing the CD69 molecule, which is known as an early activation
marker (Fig. 1A) and determined the percentage of cells having divided
within 24 h or between 24 and 48 h after mitogen or antibody
injection (Fig. 1B). Draining popliteal lymph node (PO-LN) cells
(106) were double stained with RA3-3A1 (fluorescein
isothiocyanate [FITC]-conjugated anti-murine B220; Caltag) and H1-2F3
(biotin-conjugated anti-murine CD69 [31]). Flow
cytometry was performed on a FACScan (Becton Dickinson & Co., Mountain
View, Calif.) cell analyzer.
The number of CD69+ B220+ B cells increased
from 5% in untreated control mice to as much as 95% in
mitogen-treated BALB/c mice 24 or 48 h after antibody or mitogen
injection (Fig. 1A). Due to the high amount of endogenous IgM in the
sera of normal mice, the level of activation of B cells following
anti-IgM MAb treatment was relatively low. We confirmed the effect of
each antibody treatment by surface staining of several lymphocyte
activation markers. In Fig. 1B, we show the percentage of B cells
having incorporated 5'-bromo-2'-deoxyuridine (BrdU; Sigma)
incorporation. After staining with RA3-3A1
(phycoerythrin-conjugated anti-murine B220; Caltag), fixation in
formaldehyde, and DNase treatment, flow cytometry was performed with
anti-BrdU-FITC (Becton Dickinson) (for the method used, see reference
28). One group of mice received 3 mg of BrdU
intraperitoneally and thereafter 1 mg/ml continuously in the
drinking water at the same time as mitogen or antibody, and the mice
were analyzed after 24 h. The other group of mice received BrdU
24 h after mitogen or antibody injection during a 24-h pulse.
Among the different treatment protocols, anti-CD40 induced the lowest
level of cell division, followed by LPS, and the strongest induction of
the cell cycle was found with anti-IgD or anti-IgD plus
anti-CD40. Anti-Fc
RII treatment did not lead to significant
activation and proliferation.
BALB/c mice received a single dose of mitogen s.c. (10 to 50 µg)
either before, concomitantly with, or after s.c. injection of MMTV(SW),
a retrovirus which expresses a V
6-specific Sag (108
virus particles [16]). We analyzed the percentage of
Sag-reactive V
6+ T cells in the CD4+ T-cell
population and the amount of viral DNA in the draining PO-LN at days
3.5 to 4 after infection. This time point allows measuring both reduced
or enhanced responses, since maximal stimulation was observed on days 5 to 6. In order to quantify infection levels, 500 ng of DNA of cells
extracted from the draining PO-LN was analyzed by PCR. Trace amounts of
[
-32P]dATP were added, and 30 cycles (1 cycle
consisting of 5 min at 95°C; 30 cycles with 1 cycle consisting of 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C; and, finally, an
extension step for 10 min at 72°C) were used. The Sag sequences of
the endogenous proviruses Mtv-6, Mtv-8, and
Mtv-9 were amplified as internal standards relative to
MMTV(SW) in the same tube with previously described primers
(17). This PCR method is linear for MMTV(SW) in the range of
3 to 95% of Mtv-6 signals. For weaker signals, the PCR
slightly overestimates the signals. DNA extracted from lymphocytes
derived from uninfected BALB/c mice or from PO-LN of mice 3.5 days
after injection of MMTV (3 × 106 to 3 × 108 viral particles) was used as the control. PCR products
were separated on a 6% denaturing polyacrylamide gel, which
was dried and then exposed to Kodak X-Omat film (Eastman Kodak Company,
Rochester, N.Y.). The linear range of the PCR was determined by
PhosphorImager analysis. In Fig.
2, the PCR was linear after injection of
more than 106 viral particles.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
(A) Impaired MMTV infection of mice treated with LPS.
Viral DNA was amplified from 100,000 cells isolated from the draining
PO-LN of mice 3.5 days after s.c. footpad injection of MMTV-infected
milk. LPS injection was performed at days 2, 1, 0, or +1 relative
to hind footpad injection with MMTV. LN cells from uninfected BALB/c
mice and LN cells from mice injected with virus doses ranging from
3 × 105 to 3 × 107 viral particles
were used as controls. Each lane represents the result
obtained from one mouse. The experiment was repeated three times with
similar results. (B) Impaired Sag stimulation in LPS-treated mice. In
parallel to the PCR analysis of PO-LN, LN cells were analyzed by flow
cytometry 3.5 days after MMTV infection. V 6+ cells among
CD4+ T cells were analyzed in LPS-treated mice ( ), in
MMTV-infected mice (upper hatched horizontal bar), and in
uninfected BALB/c mice (lower hatched horizontal bar). Results
were obtained with four mice.
|
|
As shown in Fig. 2A, treatment of mice with LPS before or during MMTV
challenge strongly reduced the amount of detectable viral DNA in the
draining PO-LN cells. In agreement with this, the expansion of MMTV(SW)
Sag-specific V
6+ CD4+ T cells was impaired
in LPS-treated mice (Fig. 2B). The T-cell stimulation by MMTV was
intermediate when LPS was injected 48 h before infection,
indicating that the effect of LPS was transient and partially
reversible after 48 h. One day after MMTV infection, LPS had only
a marginal inhibitory effect on the stimulation of V
6+
CD4+ T cells, as well as on infection levels. It is likely
that the events influencing the efficiency of MMTV infection were
completed within the first 24 h, before the mitogen had been given
(2).
In order to compare the effects of LPS- and other mitogen-induced
B-cell activations, we treated BALB/c mice with a single dose of either
anti-µ MAb, anti-
MAb, anti-CD40 MAb plus anti-
MAb, or
anti-CD40 MAb alone. The cross-linking of CD40 molecules on B cells has
been shown to mimic a T-helper-cell response that activates resting B
lymphocytes in vivo and to enhance the survival of B cells after
cross-linking of membrane IgD (10). Treatment of mice with a
single dose of either anti-µ MAb (Fig.
3A) or anti-
MAb (Fig. 3B) before,
during, or after MMTV challenge reduced the amount of viral DNA
recovered from the draining PO-LN in all but two samples, in which
anti-µ MAb-treated mice showed infection levels comparable to those
for controls (shown in Fig. 2A). Simultaneous injection of anti-CD40
MAb and anti-
MAb similarly reduced the PCR signals (Fig. 3C). The
effect of CD40 cross-linking on resting B cells subsequent to MMTV
infection is represented in Fig. 3D. The ratio of PCR amplification
products of MMTV(SW) versus Mtv-6 was quantitated by gel
electrophoresis and subsequent PhosphorImager analysis. Calculations of
the ratios between the MMTV(SW) and Mtv-6 PCR bands showed
that in none of the samples obtained from antibody- or LPS-treated mice
were the MMTV(SW) PCR products stronger than in mice injected with
107 viral particles. The different treatments did not
influence the absolute numbers of B cells (data not shown). Taken
together, the in vivo activation of B cells by LPS treatment or by
cross-linking of surface Ig or CD40 predominantly reduced the
efficiency of MMTV infection. There was an inverse correlation between
B-cell proliferation by mitogens on the one hand and levels of
infection and Sag response on the other hand. Therefore, we conclude
that MMTV preferentially infects naive B cells which are activated upon
infection. One of the explanations for the reduced infection levels
after preactivation might be the reduction of accessible surface
receptor structures.

View larger version (83K):
[in this window]
[in a new window]
|
FIG. 3.
Impaired MMTV infection of Ig- or anti-CD40-treated
mice. Anti-IgM (A), anti-IgD (B), anti-IgD plus anti-CD40 (C), or
anti-CD40 alone (D) was injected s.c. into the hind footpad, and
Mtv-6, Mtv-8, Mtv-9 and MMTV(SW) was
amplified by PCR from 500 ng (105 cells) of DNA of the
draining PO-LN 3.5 days after MMTV(SW) injection. The virus titration
is shown in Fig. 2A. Each lane represents the result obtained from one
mouse. The experiment was repeated three times with similar results.
|
|
In vitro studies clearly demonstrated that the B-cell activators used
in this study (LPS, anti-CD40, or anti-Ig) upregulated B7-2 and MHC
class II expression on B cells (15, 22, 23). MHC class II
expression is a prerequisite for Sag presentation of B cells,
Sag-derived T-cell-B-cell interaction, and subsequent amplification of
MMTV-infected B cells (20). Therefore, even smaller numbers
of infected cells should result in sufficient T-cell stimulation.
Analysis of the T-cell Sag response of V
6+
CD4+ T cells in LPS-, anti-IgD-, and
anti-IgD-plus-anti-CD40-treated mice, however, resulted in a strong
reduction of the Sag response (Table 1).
For anti-IgM-treated mice, only a weak inhibition was observed, most
likely due to high levels of IgM in serum. In vivo cross-linking of
CD40 did not change the percentages of V
6+
CD4+ T cells compared with infected control mice.
Our studies clearly show that MMTV infection of B cells occurs
efficiently without preactivation of the target cells, as has been
shown for HIV infection of nonproliferating monocytes and HeLa cells
(19, 30). The capability of MMTV to activate its target cell
in the early phase of infection might be an efficient strategy of
retroviruses to facilitate infection of naive target cells.
 |
ACKNOWLEDGMENTS |
We thank Jan Andersson and Antonius Rolink for MAbs 1.19, b-7-6,
and FGK 45.
This work was supported by a grant from the Swiss National Science
Foundation to H.A.-O. (grant no. 31-32271.94) and a grant from Human
Frontiers to H.A.-O. (RG-544/95).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Ludwig Institute
for Cancer Research and Institute for Biochemistry, Lausanne Branch, University of Lausanne, 1066 Epalinges, Switzerland. Phone:
41-21-6925710. Fax: 41-21-6534474. E-mail:
hacha{at}eliot.unil.ch.
 |
REFERENCES |
| 1.
|
Andersson, J.,
A. Coutinho,
W. Lernhardt, and F. Melchers.
1977.
Clonal growth and maturation to immunoglobulin secretion in vitro of every growth-inducible B lymphocyte.
Cell
10:27-34[Medline].
|
| 2.
|
Ardavin, C.,
F. Lüthi,
M. Andersson,
L. Scarpellino,
P. Martin,
H. Diggelmann, and H. Acha-Orbea.
1997.
Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model.
J. Virol.
71:7295-7299[Abstract].
|
| 3.
|
Bader, J.
1967.
A change in growth potential of cells after conversion by Rous sarcoma virus.
J. Cell. Physiol.
70:301-308[Medline].
|
| 4.
|
Bentvelzen, P., and J. Hilgers.
1980.
Murine mammary tumor virus, p. 311-355.
In
G. Klein (ed.), Viral oncology. Raven Press, New York, N.Y.
|
| 5.
|
Brines, R., and G. Klaus.
1992.
Inhibition of lipopolysaccharide-induced activation of immature B cells by anti-mu and anti-delta antibodies and its modulation by interleukin-4.
Int. Immunol.
4:765-771[Abstract/Free Full Text].
|
| 6.
|
Brines, R., and G. G. B. Klaus.
1991.
Effects of anti-immunoglobulin antibodies, interleukin-4 and second messenger agonists on B cells from neonatal mice.
Int. Immunol.
3:461-466[Abstract/Free Full Text].
|
| 7.
|
Bukrinsky, M. I.,
S. Haggerty,
M. P. Dempsey,
N. Sharova,
A. Adzhubel,
L. Spitz,
P. Lewis,
D. Goldfarb,
M. Emerman, and M. Stevenson.
1993.
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells.
Nature
365:666-669[Medline].
|
| 8.
|
Coffin, J. M.
1996.
Retroviridae and their replication, p. 1767-1847.
In
B. N. Fields, and D. M. Knipe (ed.), Virology. Raven Press Ltd., New York, N.Y.
|
| 9.
|
Defranco, A.,
E. Raveche,
R. Asofsky, and W. Paul.
1982.
Frequency of B lymphocytes responsive to anti-immunoglobulin.
J. Exp. Med.
155:1523-1536[Abstract/Free Full Text].
|
| 10.
|
Finkelman, F.,
J. Holmes,
O. Dukhanina, and S. Morris.
1995.
Cross-linking of membrane immunoglobulin D, in the absence of T cell help, kills mature B cells in vivo.
J. Exp. Med.
181:515-525[Abstract/Free Full Text].
|
| 11.
|
Finkelman, F.,
I. Scher,
J. Mond,
J. Kung, and E. Metcalf.
1982.
Polyclonal activation of the murine immune system by an antibody to IgD.I. Increase in cell size and DNA synthesis.
J. Immunol.
129:629-637[Medline].
|
| 12.
|
Fritsch, E., and H. Temin.
1977.
Formation and structure of infectious DNA of spleen necrosis virus.
J. Virol.
21:119-130[Abstract/Free Full Text].
|
| 13.
|
Gao, W.,
A. Cara,
R. Gallo, and F. Lori.
1993.
Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.
Proc. Natl. Acad. Sci. USA
90:8925-8928[Abstract/Free Full Text].
|
| 14.
|
Harel, J.,
E. Rassart, and P. Jolicoeur.
1981.
Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus.
Virology
110:202-207[Medline].
|
| 15.
|
Hathcock, K. S.,
G. Laszlo,
H. B. Dickler,
J. Bradshaw,
P. Linsley, and R. J. Hodes.
1993.
Identification of an alternative CTLA-4 ligand costimulatory for T cell activation.
Science
262:905-907[Abstract/Free Full Text].
|
| 16.
|
Held, W.,
A. N. Shakhov,
G. Waanders,
L. Scarpellino,
R. Luethy,
J. P. Kraehenbuhl,
H. R. MacDonald, and H. Acha-Orbea.
1992.
An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7).
J. Exp. Med.
175:1623-1633[Abstract/Free Full Text].
|
| 17.
|
Held, W.,
G. A. Waanders,
A. N. Shakhov,
L. Scarpellino,
H. Acha-Orbea, and H. R. MacDonald.
1993.
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission.
Cell
74:529-540[Medline].
|
| 18.
|
Julius, M.,
C. Heusser, and K. Hartmann.
1984.
Induction of resting B cells to DNA synthesis by soluble monoclonal anti-immunoglobulin.
Eur. J. Immunol.
14:753-757[Medline].
|
| 19.
|
Lewis, P.,
M. Hensel, and M. Emerman.
1992.
Human immunodeficiency virus infection of cells arrested in the cell cycle.
EMBO J.
11:3053-3058[Medline].
|
| 20.
|
Lund, F. E.,
T. D. Randall,
D. L. Woodland, and R. B. Corley.
1993.
MHC class II limits the functional expression of endogenous superantigens in B cells.
J. Immunol.
150:78-86[Abstract].
|
| 21.
|
Luther, S. L., and H. Acha-Orbea.
1997.
Mouse mammary tumor virus: immunological interplays between virus and host.
Adv. Immunol.
65:139-243[Medline].
|
| 22.
|
Mond, J.,
E. Seghal,
J. Kung, and F. Finkelman.
1981.
Increased expression of I-region-associated antigen (Ia) on B cells after cross-linking of surface immunoglobulin.
J. Immunol.
127:881-888[Abstract].
|
| 23.
|
Monroe, J., and R. J. Cambie.
1983.
Level of mIa expression on mitogen-stimulated murine B lymphocytes is dependent on position in cell cycle.
J. Immunol.
130:626-631[Abstract].
|
| 24.
|
Parker, D.
1975.
Stimulation of mouse lymphocytes by insoluble anti-mouse immunoglobulin.
Nature
258:361-363[Medline].
|
| 25.
|
Phillips, N., and D. Parker.
1984.
Cross-linking of B lymphocyte Fc receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis.
J. Immunol.
132:627-632[Abstract].
|
| 26.
|
Roe, T.,
T. C. Reynolds,
G. Yu, and P. O. Brown.
1993.
Integration of murine leukemia virus DNA depends on mitosis.
EMBO J.
12:2099-2108[Medline].
|
| 27.
|
Rolink, A.,
F. Melchers, and J. Andersson.
1996.
The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching.
Immunity
5:319-330[Medline].
|
| 28.
|
Tough, D. F.,
S. Sun, and J. Sprent.
1997.
T cell stimulation in vivo by lipopolysaccharide (LPS).
J. Exp. Med.
185:2089-2094[Abstract/Free Full Text].
|
| 29.
|
Unkeless, J. C.
1979.
Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.
J. Exp. Med.
150:580-596[Abstract/Free Full Text].
|
| 30.
|
Weinberg, J.,
T. Matthews,
B. Cullen, and M. Malim.
1991.
Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes.
J. Exp. Med.
174:1477-1482[Abstract/Free Full Text].
|
| 31.
|
Yokoyama, W.,
F. Kining,
P. J. Kehn,
G. M. B. Pereira,
G. Stingl,
J. E. Coligan, and E. M. Shevach.
1988.
Characterization of a surface-expressed disulfide-linked dimer involved in murine T cell activation.
J. Immunol.
141:369-376[Abstract].
|
Journal of Virology, September 1998, p. 7688-7691, Vol. 72, No. 9
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rassa, J. C., Meyers, J. L., Zhang, Y., Kudaravalli, R., Ross, S. R.
(2002). Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc. Natl. Acad. Sci. USA
99: 2281-2286
[Abstract]
[Full Text]
-
Finke, D., Baribaud, F., Diggelmann, H., Acha-Orbea, H.
(2001). Extrafollicular Plasmablast B Cells Play a Key Role in Carrying Retroviral Infection to Peripheral Organs. J. Immunol.
166: 6266-6275
[Abstract]
[Full Text]
-
Reilly, M., Mix, D., Reilly, A. A., Yang Ye, X., Winslow, G. M.
(2000). Intercellular Transfer of a Soluble Viral Superantigen. J. Virol.
74: 8262-8267
[Abstract]
[Full Text]